Oral administration of ACE2 in Lactobacillus paracasei could serve as protection against COVID-19 by binding SARS-CoV-2 and thus preventing its interaction with ACE2 receptors in human cells and the resulting infection [139]. This evidence concerns the gene ACE2 and infection.